Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777682 | 0.98 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP1A2MAPK1CXCR4SIGMAR1 | |
| SCHEMBL9937405 | 0.98 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP1A2MAPK1CXCR4SIGMAR1 | |
| Hydrochloric Acid SCHEMBL27554302 | 0.98 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP1A2MAPK1CXCR4SIGMAR1 | |
| SCHEMBL27793739 | 0.94 | CYP1A2 (0.57) | SMN1; SMN2CYP1A2MAPK1CXCR4SIGMAR1 | |
| SCHEMBL5865021 | 0.94 | CYP1A2 (0.57) | SMN1; SMN2CYP1A2MAPK1CXCR4SIGMAR1 | |
| SCHEMBL21727957 | 0.92 | CYP1A2 (0.55) | SMN1; SMN2CYP1A2MAPK1CXCR4SIGMAR1 | |
| Hydrochloric Acid SCHEMBL27810605 | 0.92 | CYP1A2 (0.55) | SMN1; SMN2CYP1A2MAPK1CXCR4SIGMAR1 | |
| SCHEMBL11429662 | 0.92 | CYP1A2 (0.55) | SMN1; SMN2CYP1A2MAPK1CXCR4SIGMAR1 | |
| SCHEMBL9154884 | 0.92 | CYP1A2 (0.55) | SMN1; SMN2CYP1A2MAPK1CXCR4SIGMAR1 | |
| SCHEMBL25212790 | 0.91 | CYP1A2 (0.55) | SMN1; SMN2CYP1A2MAPK1CXCR4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12517282-B2 | Contact lenses containing light absorbing regions and methods for their preparation | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| WO-2025064788-A2 | CCR5 CONJUGATES AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250018666-A1 | METHODS FOR THE MANUFACTURE OF PHOTOABSORBING CONTACT LENSES AND PHOTOABSORBING CONTACT LENSES PRODUCED THEREBY | JOHNSON & JOHNSON VISION CARE (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4453642-A1 | CONTACT LENSES CONTAINING LIGHT ABSORBING REGIONS AND METHODS FOR THEIR PREPARATION | Johnson & Johnson Vision Care, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| US-12128641-B2 | Methods for the manufacture of photoabsorbing contact lenses and photoabsorbing contact lenses produced thereby | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4334303-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230296807-A1 | CONTACT LENSES CONTAINING LIGHT ABSORBING REGIONS AND METHODS FOR THEIR PREPARATION | JOHNSON & JOHNSON VISION CARE, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230286232-A1 | METHODS FOR THE MANUFACTURE OF PHOTOABSORBING CONTACT LENSES AND PHOTOABSORBING CONTACT LENSES PRODUCED THEREBY | JOHNSON & JOHNSON VISION CARE (US) | 2023-09-14 | — | — | US | disclosed |
| US-11724471-B2 | Methods for the manufacture of photoabsorbing contact lenses and photoabsorbing contact lenses produced thereby | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2023119021-A1 | CONTACT LENSES CONTAINING LIGHT ABSORBING REGIONS AND METHODS FOR THEIR PREPARATION | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-8207163-B2 | Compositions, synthesis, and methods of using piperazine based antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2299814-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PIPERAZINE BASED ANTIPSYCHOTIC AGENTS | Reviva Pharmaceuticals, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009154993-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PIPERAZINE BASED ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| CN-1131665-A | Piperazine derivatives, medicaments comprising these compounds, their use and processes for their preparation | THOMAE GMBH DR K (DE) | 1996-09-25 | — | — | CN | disclosed |
| US-5215974-A | Antisecretory agents for gastrointestinal disorders; water solubility, chemical stability | AKTIEBOLAGET HASSLE (SE) | 1993-06-01 | — | — | US | disclosed |
| EP-0332647-A1 | NEW BENZIMIDAZOLE DERIVATIVES A PROCESS FOR PRODUCTION THEREOF AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Aktiebolaget Hässle (SE) | 1989-09-20 | — | — | EP | disclosed |
| WO-1988003921-A1 | NEW BENZIMIDAZOLE DERIVATIVES A PROCESS FOR PRODUCTION THEREOF AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Aktiebolaget Hässle (SE) | 1988-06-02 | — | — | WO | disclosed |
| US-4220704-A | Water soluble photosensitive resin compositions comprising a polyamide or its salt | TOYOBO CO., LTD. (JP) | 1980-09-02 | — | — | US | disclosed |
| US-4145222-A | Water soluble photosensitive resin composition comprising a polyamide or its ammonium salt | TOYOBO CO., LTD. (JP) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | GRIK5, GAP43, GRIN2D | SMN1; SMN2 3263/4885CYP1A2 502/4885MAPK1 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.